Digitisation | January 10, 2026
Revvity and Lilly partner to accelerate AI drug discovery models
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The accelerated review covers WCK 5222 for multiple critical infections
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Harbour BioMed brings advanced antibody discovery platforms to the table
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
Subscribe To Our Newsletter & Stay Updated
